Evidence map›Paper›PMID 25035659›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014

Association between hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls.

Tao Tao, Shuqiu Chen, Bin Xu, Chunhui Liu, Yiduo Wang, Yeqing Huang, Ming Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Pri-miR-34b/c rs4938723 polymorphism increased the risk of prostate cancer.Cancer biomarkers : section A of Disease markers · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tao Tao1 Department of Urology, Affiliated Zhongda Hospital, Medical School, 2 Surgical Research Center, Medical School, 3 Institute of Urology, Southeast University, Nanjing 210009, China.
Shuqiu Chen1 Department of Urology, Affiliated Zhongda Hospital, Medical School, 2 Surgical Research Center, Medical School, 3 Institute of Urology, Southeast University, Nanjing 210009, China.
Bin Xu1 Department of Urology, Affiliated Zhongda Hospital, Medical School, 2 Surgical Research Center, Medical School, 3 Institute of Urology, Southeast University, Nanjing 210009, China.
Chunhui Liu1 Department of Urology, Affiliated Zhongda Hospital, Medical School, 2 Surgical Research Center, Medical School, 3 Institute of Urology, Southeast University, Nanjing 210009, China.
Yiduo Wang1 Department of Urology, Affiliated Zhongda Hospital, Medical School, 2 Surgical Research Center, Medical School, 3 Institute of Urology, Southeast University, Nanjing 210009, China.
Yeqing Huang1 Department of Urology, Affiliated Zhongda Hospital, Medical School, 2 Surgical Research Center, Medical School, 3 Institute of Urology, Southeast University, Nanjing 210009, China.
Ming Chen1 Department of Urology, Affiliated Zhongda Hospital, Medical School, 2 Surgical Research Center, Medical School, 3 Institute of Urology, Southeast University, Nanjing 210009, China.
Zhongda Hospital Southeast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEmerging evidence shows that microRNAs (miRNAs) function as tumor suppressors or oncogenes in human carcinogenesis. A single nucleotide polymorphism (SNP) located in the pri-miRNA promoter may affect the processing and expression of mature miRNA. However, previous studies showed conflicting results regarding the association of hsa-miR-34b/c rs4938723 T > C promoter polymorphism with cancer. Therefore, we conducted a meta-analysis to determine the association of polymorphism with cancer risk.

methodsA computerized search of PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI) for publications on hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk was performed and the genotype data were analyzed in a meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association. Test of heterogeneity, cumulative meta-analysis, sensitivity analysis and assessment of bias were performed in our meta-analysis by STATA software 12.0.

resultsThere was no significant association between hsa-miR-34b/c rs4938723 polymorphism and overall cancer risk in the comparison models. Moreover, subgroup analysis revealed that the variant CT (OR =1.19, 95% CI: 1.03-1.37) and CC/CT (OR =1.18, 95% CI: 1.03-2.35) genotypes were associated with an increased risk of hepatocellular carcinoma (HCC) compared with wild-type TT genotype. However, a decreased risk of colorectal cancer (CRC) was found in the genetic model of CC/TT (OR =0.66, 95% CI: 0.47-0.92) and CC/CTTT (OR =0.67, 95% CI: 0.49-0.93).

conclusionsThe results suggest that hsa-miR-34b/c rs4938723 polymorphism may play an opposite role in different types of cancer based on current studies, which is the main origin of heterogeneity in this meta-analysis. Further large-scale studies and functional studies between this polymorphism and cancer risk are warranted.

Indexed as

cancerHsa-miR-34b/cmeta-analysispolymorphism

Identifiers

PMID25035659
PMCPMC4076713
OpenAlexW1856608847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.